What did Cowen change about the RPRX analyst rating on Feb 27, 2026?

Cowen & Co. maintained its **Buy** rating on **Feb 27, 2026** and raised the price target to **$50**, signaling continued confidence in Royalty Pharma’s royalty cash flows without upgrading to a stronger rating.

How should investors interpret a maintained Buy with a higher price target?

A maintained Buy with a raised target means analysts see upside but not a dramatic shift in fundamentals; the RPRX analyst rating suggests holding or selective accumulation versus immediate trading based on conference catalysts.

Did the RPRX analyst rating update move the stock?

Yes, the update coincided with a short-term decline of **1.84% ($0.85)**, showing that price-target changes can prompt profit-taking even when ratings stay positive.

What is Meyka AI’s view on RPRX after the rating action?

Meyka AI rates RPRX with a **B+**, reflecting S&P 500 comparison, sector performance, growth metrics, and analyst consensus; this grade is informational and not financial advice.

Analyst Ratings

Cowen Maintains Buy on Royalty Pharma plc (RPRX) Feb 27, 2026

ByDanny Kontos February 28, 2026February 28, 2026

Cowen & Co. maintained its Buy rating on Royalty Pharma plc (RPRX) on Feb 27, 2026, while raising the price target to $50 and signaling continued confidence in the company’s royalty portfolio. The RPRX analyst rating update keeps the Buy view but tightens the upside math for investors after the target bump. The StreetInsider note reports a -1.84% intraday move, reflecting short-term profit taking against a $19,797,506,820 market capitalization. Meyka AI’s real-time coverage flags this as a vote of confidence ahead of Royalty Pharma’s upcoming TD Cowen conference appearance StreetInsider source.